WAT Waters (WAT) Insider Trading, Ownership & Congress Trades
Medical Devices · Laboratory analytical instruments · CIK 0001000697
Congress · 2Form 144 · 1
Insider buyers, 180 days
0
Funds added, last quarter
517
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $494.7K priced
What the filings say about WAT
Insiders, 180 days
-$1.4M net sold
1 seller · 0% of sales under a 10b5-1 plan
Congress, 1 year
2 bought · 2 sold
Latest: sale, 2026-08-13
Planned sales (Form 144), 90 days
$1.4M
1 notice
Waters insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, WATERS CORP /DE/ insiders sold a net $1.4M of stock across 22 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on May 15, 2024.
- The trade is 20.4% of the 17,808 shares held after it.
- No other insider sold within 30 days.
- 517 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director KUEBLER CHRISTOPHER A sold about $1.4M of WAT on Aug 6, 2026, the largest insider sale at the company since 2024; 517 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 14.5% of the 3,441 shares held after it.
- 1 other insider bought within 30 days.
- 517 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Jiang Wei bought about $144.7K of WAT on Mar 16, 2026; 1 other insider bought within 30 days and 517 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 28, 2024.
- The trade is 30.3% of the 3,302 shares held after it.
- 1 other insider bought within 30 days.
- 517 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director FEARON RICHARD H bought about $306.3K of WAT on Mar 6, 2026, the largest insider purchase at the company since 2024; 1 other insider bought within 30 days and 517 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 60.5% of the 1,653 shares held after it.
- No other insider bought within 30 days.
- 517 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director FEARON RICHARD H bought about $332.9K of WAT on May 28, 2024, the largest insider purchase at the company since 2023; 517 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Aug 4, 2023.
- The trade is 27.2% of the 14,716 shares held after it.
- No other insider sold within 30 days.
- 517 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director KUEBLER CHRISTOPHER A sold about $1.4M of WAT on May 15, 2024, the largest insider sale at the company since 2021; 517 funds added in the latest 13F quarter.22 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$1.4M over 180 days
-$1.4M over 90 days
below 65% of Medical Devices
Congress
2 members bought in the last year
more than 81% of Medical Devices
Funds
517 funds bought in last quarter
more than 95% of Medical Devices
Revenue
+7.0% year over year
below 58% of Medical Devices
Margin
20.3% net margin
more than 93% of Medical Devices
Buybacks
$14.0M repurchased, FY to 2026-07-04
below 56% of Medical Devices
Short interest
3.2% of the float short (float per yahoo 2026-10-27) · 3.4 days to cover · settled 2026-10-15
below 51% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch WAT
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+31.7%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns WAT: institutional holders (13F)
13F holdings, latest reported quarter
8,484,939 sh
$3.2B
4,625,035 sh
$2.5B
6,415,552 sh
$2.4B
4,740,524 sh
$1.8B
4,382,008 sh
$1.6B
Congress trades in WAT
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-08-13 · disclosed 19 days later
$1,001 - $15,000
Bought 2026-03-18 · disclosed 20 days later
$1,001 - $15,000
Sold 2026-03-10 · disclosed 34 days later
$1,001 - $15,000
Sold 2026-02-13 · disclosed 33 days later
$1,001 - $15,000
Exchanged 2026-02-10 · disclosed 13 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
WAT planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
KUEBLER CHRISTOPHER A
Filed 2026-08-06
$1.4M
WAT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Water Resources ETF
$134.9M position · as of 2026-07-31
6.7%
First Trust Water ETF
$90.3M position · as of 2026-06-30
4.9%
BECK, MACK & OLIVER PARTNERS FUND
$3.4M position · as of 2026-06-30
4.4%
FULLERTHALER BEHAVIORAL UNCONSTRAINED EQUITY
$40.8M position · as of 2026-06-30
4.3%
Motley Fool Mid-Cap Growth ETF
$4.5M position · as of 2026-05-31
3.9%
Invesco Global Water ETF
$10.5M position · as of 2026-07-31
3.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
People Helping People
Cycle 2026 · $59K spent
$70.0K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Dr.Batra
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$11.1M
$14.6M
$2.5M
+50%
-28%
2023
$8.7M
-$1.1M
$2.3M
+33%
-24%
2022
$9.4M
$10.8M
$2.7M
+38%
-14%
2021
$8.7M
$19.1M
$2.4M
+51%
+27%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.4M sold by insiders over 180 days, 517 funds added last quarter, 2 House member(s) bought in 12 months, disclosed weeks after the trade, $1.4M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
WAT financials
Revenue growth
+7.0%
XBRL, annual
Net margin
20.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.6B
four quarters, 2025-07-01 to 2026-07-04
Revenue, TTM WAT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jul 2026 | $1.6B |
| Apr 2026 | $1.3B |
| Dec 2025 | $932.4M |
| Sep 2025 | $799.9M |
| Sep 2025 | $799.9M |
| Jun 2025 | $771.3M |
| Jun 2025 | $771.3M |
| Mar 2025 | $661.7M |
At each fiscal year end
Single quarter
Net margin, TTM
+3.6%
net income over revenue, 2025-06-29 to 2026-07-04
Net margin, TTM WAT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jul 2026 | -8.3% |
| Apr 2026 | -5.7% |
| Dec 2025 | +24.2% |
| Sep 2025 | n/a |
| Sep 2025 | +18.6% |
| Jun 2025 | n/a |
| Jun 2025 | +19.1% |
| Mar 2025 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM WAT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jul 2026 | $153.0M |
| Apr 2026 | -$42.0M |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Jun 2025 | $18.0M |
| Mar 2025 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.32x
long-term 2026-07-04 plus current 2021-12-31 (54 months older than the period end); equity 2026-07-04
Debt to equity WAT
| FY Dec 2025 | 0.37x |
| FY Dec 2024 | 0.89x |
| FY Dec 2023 | 2.00x |
| FY Dec 2022 | 3.02x |
| FY Dec 2021 | 4.12x |
| Jul 2026 | 0.32x |
| Apr 2026 | 0.32x |
| Dec 2025 | 0.37x |
| Sep 2025 | 0.41x |
| Sep 2025 | 0.41x |
| Jun 2025 | 0.55x |
| Jun 2025 | 0.55x |
| Mar 2025 | 0.69x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.11x
TTM operating cash flow over long-term 2026-07-04 plus current 2021-12-31 (54 months older than the period end)
Cash flow to debt WAT
| FY Dec 2025 | 0.69x |
| FY Dec 2024 | 0.47x |
| FY Dec 2023 | 0.26x |
| FY Dec 2022 | 0.40x |
| FY Dec 2021 | 0.49x |
| Jul 2026 | 0.11x |
| Apr 2026 | 0.08x |
| Dec 2025 | 0.69x |
| Sep 2025 | 0.77x |
| Sep 2025 | 0.77x |
| Jun 2025 | 0.62x |
| Jun 2025 | 0.62x |
| Mar 2025 | 0.56x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+1.9%
TTM net income over average of 2025-06-28 and 2026-07-04
Return on equity WAT
| FY Dec 2025 | +29.2% |
| FY Dec 2024 | +42.8% |
| FY Dec 2023 | +77.6% |
| FY Dec 2022 | +162.3% |
| FY Dec 2021 | +231.1% |
| Jul 2026 | +1.9% |
| Apr 2026 | +5.2% |
| Dec 2025 | +29.2% |
| Sep 2025 | +33.0% |
| Sep 2025 | +33.0% |
| Jun 2025 | +37.0% |
| Jun 2025 | +37.0% |
| Mar 2025 | +40.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+1.1%
TTM net income over average of 2025-06-28 and 2026-07-04
Return on assets WAT
| FY Dec 2025 | +13.3% |
| FY Dec 2024 | +13.9% |
| FY Dec 2023 | +16.2% |
| FY Dec 2022 | +22.2% |
| FY Dec 2021 | +23.3% |
| Jul 2026 | +1.1% |
| Apr 2026 | +3.1% |
| Dec 2025 | +13.3% |
| Sep 2025 | +13.8% |
| Sep 2025 | +13.8% |
| Jun 2025 | +14.4% |
| Jun 2025 | +14.4% |
| Mar 2025 | +14.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+2.0%
operating income after a 19.1% effective tax rate, over long-term 2026-07-04 plus current 2021-12-31 (54 months older than the period end) plus average of 2025-06-28 and 2026-07-04 minus cash
Return on invested capital WAT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jul 2026 | +2.0% |
| Apr 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+2.5%
operating income (EBIT proxy) over average of 2025-06-28 and 2026-07-04 minus current liabilities
Return on capital employed WAT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jul 2026 | +2.5% |
| Apr 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
116.85x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-07-04
P/E, trailing WAT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jul 2026 | 94.59x |
| Apr 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$50.4B
market value at close 2026-10-27 on 2026-08-07 shares, plus long-term 2026-07-04 plus current 2021-12-31 (54 months older than the period end), minus cash 2026-07-04
Enterprise value WAT
| FY Dec 2025 | $23.0B |
| FY Dec 2024 | $23.3B |
| FY Dec 2023 | $21.4B |
| FY Dec 2022 | $21.4B |
| FY Dec 2021 | $23.8B |
| Jul 2026 | $41.6B |
| Apr 2026 | $34.2B |
| Dec 2025 | $23.0B |
| Sep 2025 | $18.3B |
| Sep 2025 | $17.9B |
| Jun 2025 | $21.6B |
| Jun 2025 | $21.8B |
| Mar 2025 | $22.9B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield WAT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
no prior four-quarter EPS window to measure growth
PEG, trailing WAT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $3.2B | $3.0B | $3.0B | $3.0B |
| Operating income | $802.6M | $826.4M | $817.7M | $873.4M |
| Net income | $642.6M | $637.8M | $642.2M | $707.8M |
| EPS (diluted) | 10.76 | 10.71 | 10.84 | 11.73 |
| Operating cash flow | $652.6M | $762.1M | $602.8M | $611.7M |
| Cash | $588.0M | $325.4M | $395.1M | $480.5M |
| Long-term debt | $947.0M | $1.6B | $2.3B | $1.5B |
| Buybacks | $14.7M | $13.5M | $70.3M | $626.1M |
SEC XBRL, fiscal years, as known on 2026-10-28
WAT Stock Sonar score 6/7 axes
Find similar shapesCompareWAT ranks highest on institutional and government (67th percentile) and growth (63rd), and lowest on insider conviction (17th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
WAT filings, in plain words
Are Waters insiders buying or selling WAT?
In the 180 days to 2026-10-28, Waters insiders were net sellers, a net $1.4M across purchases and sales reported on Form 4, by 1 seller.
Have members of Congress traded WAT?
Yes. In the year to 2026-10-28, 2 House members disclosed buying WAT and 2 House members disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-08-13.
Are there planned insider sales of WAT?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $1.4M of stock; the latest, by KUEBLER CHRISTOPHER A, was filed 2026-08-06.
Read the full summary
In the 180 days to 2026-10-28, Waters insiders were net sellers of WAT, a net $1.4M across purchases and sales reported on Form 4 by 1 seller. In the year to 2026-10-28, 2 members of Congress disclosed buying WAT and 2 members disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-08-13. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $1.4M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
